Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
根據最新的財務報表(Form-10K),Virax Biolabs Group Ltd 的總資產為 $6,淨損失為 $-6
VRAX 的關鍵財務比率是什麼?
Virax Biolabs Group Ltd 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Virax Biolabs Group Ltd 的收入按細分市場或地理位置如何劃分?
Virax Biolabs Group Ltd 最大收入來源為 ViraxClear and ViraxVet,在最近的收益報告中收入為 156,419。就地區而言,United Kingdom, Hong Kong, Singapore, China, British Virgin Islands 是 Virax Biolabs Group Ltd 的主要市場,收入為 156,419。